A 68-year-old man presents to the urology clinic with a 2-year history of progressive lower urinary tract symptoms (LUTS). He reports nocturia 4–5 times per night, weak urinary stream, hesitancy, and incomplete emptying. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate without nodules. Post-void residual (PVR) is 120 mL. Serum PSA is 2.8 ng/mL. Uroflowmetry shows peak flow of 8 mL/s (normal >15 mL/s). He has tried lifestyle modifications without improvement. What is the most appropriate next step in management?

Explanation

## Clinical Presentation & Diagnosis This patient has **symptomatic benign prostatic hyperplasia (BPH)** with moderate LUTS, reduced peak urinary flow (8 mL/s), and elevated post-void residual (120 mL). The smooth, symmetrical prostate on DRE and normal PSA exclude malignancy. ## Medical Management Hierarchy **Key Point:** Alpha-1 adrenergic antagonists (α1-blockers) are the first-line pharmacological agent for symptomatic BPH, regardless of prostate size. **High-Yield:** The treatment algorithm for BPH follows a stepwise approach: | Stage | Management | Indication | |-------|------------|------------| | Mild symptoms (IPSS <8) | Watchful waiting, lifestyle modification | Minimal bother | | Moderate symptoms (IPSS 8–19) + no obstruction | α1-blocker monotherapy | First-line medical | | Moderate symptoms + large prostate (>40 g) | α1-blocker + 5α-reductase inhibitor | Combination therapy | | Severe symptoms (IPSS ≥20) or failure of medical Rx | Surgical intervention (TURP, laser, open) | Refractory disease | ## Why α1-Blocker First? 1. **Rapid symptom relief:** Works within 1–2 weeks (acts on smooth muscle in prostate capsule and bladder neck). 2. **Mechanism:** Blocks α1A-adrenergic receptors → reduces dynamic obstruction. 3. **Safety:** Minimal side effects; no hormonal effects. 4. **Evidence:** Standard first-line per EAU, AUA, and Indian urology guidelines. **Clinical Pearl:** 5-alpha reductase inhibitors (finasteride, dutasteride) take 6–12 months to show effect and are reserved for large glands (>40 g) or used as combination therapy. They reduce prostate volume by ~25% but do not provide immediate symptom relief. ## Why Not TURP Yet? TURP is indicated for: - **Refractory LUTS** despite adequate medical therapy (≥3–6 months). - **Complications:** recurrent UTIs, bladder stones, refractory retention. - **Severe symptoms** (IPSS ≥20) with patient preference for definitive treatment. This patient has not yet had a trial of medical therapy. **Warning:** Suprapubic catheterization is a temporizing measure for acute retention, not definitive BPH management.